AAV-based gene editing of type 1 collagen mutation to treat osteogenesis imperfecta is a research paper published in Molecular Therapy — Nucleic Acids (2023). On theSindex it has a DataRank of 0. It has been cited 20 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 5R01NS076991-07
Novel Gene Therapy Strategies for Canavan Disease
National Institutes of Health
Grant: 5R01AI121135-05
Fcgamma receptor-mediated suppression of immunodeficiency virus replication
National Institutes of Health
Grant: 5P01HL131471-02
New Approaches to Gene Therapy for Alpha-1 Antitrypsin Deficiency
National Institutes of Health
Grant: 6U19AI149646-03
An AAV-mediated functional cure and its impact on the reservoir
National Institutes of Health
Grant: 1R01HL097088-01A2
Next Generation of Recombinant AAV Serotype Vectors for Gene Therapy
National Institutes of Health
Grant: 5UG3HL147367-03
Develop combinatorial non-viral and viral CRISPR delivery for lung diseases
National Institutes of Health
Grant: 1R01HL152723-01A1
Fortilin, CTNNA3, and the Heart
NHLBI NIH HHS
Grant: UH3 HL147367
NHLBI NIH HHS
Grant: UG3 HL147367
NHLBI NIH HHS
Grant: R01 HL097088
NIAMS NIH HHS
Grant: R21 AR079633
NHLBI NIH HHS
Grant: P01 HL131471
NIAID NIH HHS
Grant: U19 AI149646
NIAID NIH HHS
Grant: R01 AI121135
NINDS NIH HHS
Grant: R01 NS076991
NHLBI NIH HHS
Grant: R01 HL152723
FWCI
2.93
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals